All Regulation articles – Page 7
-
BusinessAddressing the saga of nitrosamine contamination in drugs
Scientific and regulatory progress is helping minimise the impact of mutagenic impurities
-
BusinessTornado at Pfizer plant accentuates US drug shortage issues
Perennial problem will not be addressed without major reforms to drug market
-
BusinessLapsed US chemical security programme leaves facilities vulnerable
Chemical Facility Anti-Terrorism Standards’ expiry means rules will not be enforced, and companies cannot vet new staff
-
NewsEuropean intellectual property system ready for gene-edited crops
Updates to New Genomic Technology regulations irrelevant to IP say experts
-
OpinionResistant to change
Curbing industrial practices that drive antimicrobial resistance needs tighter regulation and enforcement
-
NewsUS safety board warns of hurricane threat to chemical facilities
US Federal Energy Reculatory Commission overlooked hurricane threat in guidance governing transmission system planning requirements
-
NewsDispute over formaldehyde toxicity assessment escalates
US scientific academy finds EPA’s review linking formaldehyde to cancer is supported by evidence, chemical industry pushes back with lawsuit
-
BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
-
NewsLow UK carbon prices ‘disincentivise’ investment in decarbonisation technology
Changes to the UK’s emissions trading scheme could damage the chances of reaching net zero
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessIllumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
OpinionWho knew what? And when?
Finding the line between commercially sensitive information and public and environmental protection
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
BusinessEnvironmental groups claim US herbicide reapprovals were illegal
Lawsuit says Environmental Protection Agency ignored serious risks with 2,4-D-containing Enlist products
-
OpinionBringing drug manufacturing back home
Pharmaceutical supply chains are international, complex and opaque. Is there a better way?
-
BusinessUK diverges from EU rules with cosmetics animal testing ban
UK will no longer allow Reach-required animal tests intended to prove worker safety
-
BusinessChemical firms kept data on PFAS health hazards secret
Documents suggest that DuPont and 3M had evidence of PFAS toxicity but suppressed the findings
-
BusinessUS trade regulator sues to block Amgen–Horizon merger
Federal Trade Commission has concerns that union will allow Amgen to stifle potential competition for Horizon’s drugs
-
BusinessThe diabetes drugs aiming to aid weight loss
Can peptide hormone mimics avoid the side effect pitfalls of previous weight loss treatments?
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards